| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
57,680,000 |
| Market
Cap: |
1.71(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.05 - $32.15 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
93,396 |
175,244 |
175,244 |
175,244 |
| Total Sell Value |
$2,858,339 |
$4,519,351 |
$4,519,351 |
$4,519,351 |
| Total People Sold |
3 |
5 |
5 |
5 |
| Total Sell Transactions |
6 |
9 |
9 |
9 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gupta Suneel |
EVP Clinical Operations |
• – – |
2019-12-03 |
4 |
B |
$5.13 |
$153,900 |
D/D |
30,000 |
49,500 |
2.74 |
- |
|
| Kalkofen Donald A. |
Chief Financial Officer |
• – – |
2019-12-03 |
4 |
B |
$5.09 |
$5,987 |
D/D |
1,175 |
1,175 |
2.74 |
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2019-12-03 |
4 |
B |
$5.55 |
$168,500 |
D/D |
30,000 |
409,824 |
2.81 |
- |
|
| Giraudo Bryan |
Director |
– • – |
2019-12-03 |
4 |
B |
$5.70 |
$45,620 |
I/I |
8,000 |
8,000 |
2.1 |
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2019-08-06 |
4 |
S |
$8.85 |
$95,535 |
D/D |
(10,792) |
374,792 |
|
- |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2019-08-06 |
4 |
S |
$8.85 |
$30,044 |
D/D |
(3,395) |
49,802 |
|
- |
|
| Selick Harold E |
Director |
– • – |
2019-04-01 |
4 |
OE |
$1.31 |
$4,336 |
D/D |
3,310 |
3,310 |
|
- |
|
| Shame Richard S |
Chief Medical Officer |
• – – |
2019-03-01 |
4 |
S |
$8.03 |
$5,276 |
D/D |
(657) |
32,021 |
|
- |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2019-03-01 |
4 |
S |
$8.03 |
$6,504 |
D/D |
(810) |
51,197 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2019-03-01 |
4 |
S |
$8.03 |
$17,529 |
D/D |
(2,183) |
383,831 |
|
- |
|
| Shame Richard S |
Chief Medical Officer |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
8,500 |
32,678 |
|
- |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
52,007 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
386,014 |
|
- |
|
| Gupta Suneel |
EVP Clinical Operations |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
17,500 |
|
- |
|
| Saks Samuel R |
Chief Development Officer |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Shame Richard S |
Chief Medical Officer |
• – – |
2019-02-06 |
4 |
S |
$7.71 |
$21,506 |
D/D |
(2,778) |
24,178 |
|
- |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2019-02-06 |
4 |
S |
$7.74 |
$29,562 |
D/D |
(3,821) |
37,007 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2019-02-06 |
4 |
S |
$7.71 |
$84,410 |
D/D |
(10,909) |
357,264 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2019-01-11 |
4 |
OE |
$1.16 |
$25,919 |
D/D |
22,344 |
368,173 |
|
- |
|
| Oneil Thomas P. |
Chief Financial Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,100 |
30,560 |
|
- |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
25,800 |
40,828 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
82,050 |
345,829 |
|
- |
|
| Shame Richard S |
Chief Medical Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
18,750 |
26,956 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2018-07-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
263,779 |
|
- |
|
| Canaan Partners X Llc |
10% Owner |
– – • |
2018-05-17 |
4 |
S |
$6.09 |
$237,358 |
D/D |
(38,968) |
2,116,552 |
|
- |
|
166 Records found
|
|
Page 4 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.29 (0.99%) 
